Fergene
FerGene is a new gene therapy company dedicated to creating and delivering innovative solutions to urologists and those affected by non-muscle invasive bladder cancer (NMIBC). Our goal is to provide greater hope to patients with this disease, who have seen little improvement in their standard of care over the past 20 years. FerGene, Inc. is a privately held company, created through a joint partnership between Ferring Pharmaceuticals and Blackstone Life Sciences. With over $570 million in funding, FerGene is preparing to commercialize nadofaragene firadenovec (rAd-IFN/Syn3) for high-grade, BCG-unresponsive NMIBC for the US market. Phase 3 data for nadofaragene firadenovec were presented at the Society of Urologic Oncology Congress in December 2019.
7-day free trial · no credit card
Verified contacts
1
available on Kipplo
LinkedIn employees
11 to 50
headcount range
Open roles
—
no listings
Distinct roles
1
indexed titles
Tech stack
0
tools in use
Monthly traffic
—
organic / mo
Sign up free to see all 1 verified contacts at Fergene
Free for 7 days · 50 credits · no card · only pay for verified records.
Decision-makers and verified team members
1 contacts with verified email or phone · masked until revealed.
No verified contacts on record for this company yet.
Top roles at Fergene
1 distinct titles indexed · top 1 shown.
- 1dirigente del servizio
Sign up to unlock all 1 contacts at Fergene
Free for 7 days · 50 credits · no card · only pay for verified records.
Sign up to reveal 1 verified contacts at Fergene
7-day trial · no credit card · cancel anytime · only pay for verified records.
Trusted by sales, marketing, and GTM engineering teams.